Compare SDEV & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDEV | MDXH |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.3M | 68.7M |
| IPO Year | 2007 | 2021 |
| Metric | SDEV | MDXH |
|---|---|---|
| Price | $3.66 | $0.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.80 |
| AVG Volume (30 Days) | ★ 5.9M | 195.2K |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.42 | N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $370,000.00 | N/A |
| Revenue This Year | N/A | $5.40 |
| Revenue Next Year | N/A | $12.92 |
| P/E Ratio | $0.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $0.40 |
| 52 Week High | $3.40 | $5.33 |
| Indicator | SDEV | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 82.32 | 43.94 |
| Support Level | $0.93 | $0.51 |
| Resistance Level | N/A | $0.75 |
| Average True Range (ATR) | 0.30 | 0.05 |
| MACD | 0.27 | -0.01 |
| Stochastic Oscillator | 95.70 | 30.95 |
Stablecoin Development Corp is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.